Supplementary Figure 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
<p>Supplementary Figure 3. Shannon diversity index at baseline for AS subgroups and according to best overall response rate.</p>
Authors
- Thomas H. A. Ederveen (ORCID: https://orcid.org/0000-0003-0068-1275)
- Kalijn F. Bol (ORCID: https://orcid.org/0000-0003-4165-2040)
- Uta Flucke (ORCID: https://orcid.org/0000-0003-0315-4307)
- Stefan G. van Ravensteijn (ORCID: https://orcid.org/0000-0003-4069-3932)
- Tessa J.J. de Bitter (ORCID: https://orcid.org/0000-0002-8669-3834)
- Mark A.J. Gorris (ORCID: https://orcid.org/0000-0003-3621-226X)
- Yvonne M.H. Versleijen‐Jonkers (ORCID: https://orcid.org/0000-0001-7623-0505)
- Jacco J. de Haan (ORCID: https://orcid.org/0000-0002-1629-4715)
- Suzanne E. J. Kaal (ORCID: https://orcid.org/0000-0002-8063-0074)
- Melissa H.S. Hillebrandt-Roeffen
- Hans A. J. Gelderblom (ORCID: https://orcid.org/0000-0001-9270-8636)
- Carla M.L. van Herpen (ORCID: https://orcid.org/0000-0001-5130-5451)
- Ingrid M.E. Desar (ORCID: https://orcid.org/0000-0003-0945-8299)
- Annemarie Boleij (ORCID: https://orcid.org/0000-0003-4495-5880)
- Minke Smits (ORCID: https://orcid.org/0000-0003-1360-7285)
- Frank M. Speetjens (ORCID: https://orcid.org/0000-0003-2065-9593)
- Maikel J.L. Nederkoorn
- Han J. Bonenkamp (ORCID: https://orcid.org/0000-0002-3608-4184)
- Alem Gusinac
Publication Details
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1158/1078-0432.30029527
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00